Last reviewed · How we verify
(TauroLock Hep500)
TauroLock Hep500 is a catheter lock solution that prevents bacterial biofilm formation and thrombosis in central venous catheters through a combination of taurolidine and heparin.
TauroLock Hep500 is a catheter lock solution that prevents bacterial biofilm formation and thrombosis in central venous catheters through a combination of taurolidine and heparin. Used for Prevention of catheter-related bloodstream infections (CRBSI) in patients with central venous catheters, Prevention of catheter thrombosis in hemodialysis and parenteral nutrition patients.
At a glance
| Generic name | (TauroLock Hep500) |
|---|---|
| Sponsor | Hamad Medical Corporation |
| Drug class | Catheter lock solution |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Vascular Access |
| Phase | FDA-approved |
Mechanism of action
Taurolidine is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and prevents biofilm formation on catheter surfaces, while heparin (500 IU/mL) provides anticoagulant activity to prevent catheter thrombosis. This dual mechanism reduces both infectious and thrombotic complications associated with long-term central venous catheter use.
Approved indications
- Prevention of catheter-related bloodstream infections (CRBSI) in patients with central venous catheters
- Prevention of catheter thrombosis in central venous catheters
Common side effects
- Local catheter site reactions
- Catheter dysfunction
- Hypersensitivity reactions
Key clinical trials
- Taurolidine in Haemodialysis Catheter Related Bacteraemia (PHASE4)
- Taurolock Hep 500 Versus Unfractionated Heparin as Anti-inflammatory in Hemodialysis Catheters. (PHASE4)
- Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase (PHASE3)
- Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction (PHASE4)
- Management of Tunneled Catheter Thrombosis in Hemodialysis Patients: Prospective Study From Qatar (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- (TauroLock Hep500) CI brief — competitive landscape report
- (TauroLock Hep500) updates RSS · CI watch RSS
- Hamad Medical Corporation portfolio CI